Scilex Holding (SCLXW) Equity Average (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Equity Average of -$230.9 million in Q1 2026, down 20.05% quarter-over-quarter from -$192.4 million in Q4 2025, and down 14.28% on a YoY basis from -$269.4 million in Q1 2025.
Scilex Holding (SCLXW) Equity Average (2020 - 2026) Analysis & Trends
Scilex Holding's Equity Average history runs 7 years deep, the most recent figure standing at -$230.9 million for Q1 2026.
- In Q1 2026, Equity Average fell 14.28% year-over-year to -$230.9 million; the TTM figure through Mar 2026 stood at -$230.9 million (down 14.28% YoY), while the FY2025 annual figure was -$200.2 million, down 9.53% from the prior year.
- Equity Average was -$230.9 million for Q1 2026 at Scilex Holding, down from -$192.4 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $23.7 million in Q1 2023 to a low of -$241.8 million in Q2 2022.
- Historically, Equity Average has averaged -$169.6 million across 5 years, with a median of -$202.1 million in 2025.
- The sharpest annual moves came in 2022 and 2023: Equity Average tumbled 2824.72% in 2022, then surged 110.39% in 2023.
- A 5-year view of Equity Average shows it stood at -$96.6 million in 2022, then sank by 73.75% to -$167.8 million in 2023, then declined by 20.37% to -$202.0 million in 2024, then rose by 4.76% to -$192.4 million in 2025, then fell by 20.05% to -$230.9 million in 2026.
- The last three Equity Average figures came in at -$230.9 million (Q1 2026), -$192.4 million (Q4 2025), and -$213.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 28.87 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 81.37 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -4.96 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 49.27 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 8.92 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 23.11 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 88.29 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 19.27 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | -230.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -230.93 Mn |
| Dec 31, 2025 | -192.36 Mn |
| Sep 30, 2025 | -212.96 Mn |
| Jun 30, 2025 | -230.24 Mn |
| Mar 31, 2025 | -202.06 Mn |
| Dec 31, 2024 | -201.98 Mn |
| Sep 30, 2024 | -213.00 Mn |
| Jun 30, 2024 | -202.24 Mn |
| Mar 31, 2024 | -181.36 Mn |
| Dec 31, 2023 | -167.80 Mn |
| Sep 30, 2023 | -76.13 Mn |
| Jun 30, 2023 | 10.75 Mn |
| Mar 31, 2023 | 23.66 Mn |
| Dec 31, 2022 | -96.58 Mn |
| Sep 30, 2022 | -240.75 Mn |
| Jun 30, 2022 | -241.83 Mn |
| Mar 31, 2022 | -227.72 Mn |
| Dec 31, 2021 | -116.85 Mn |
| Sep 30, 2021 | -9.11 Mn |
| Jun 30, 2021 | -8.27 Mn |